CN104161769B - A kind of compositions containing adenosine cyclophosphate and application thereof - Google Patents
A kind of compositions containing adenosine cyclophosphate and application thereof Download PDFInfo
- Publication number
- CN104161769B CN104161769B CN201410404023.9A CN201410404023A CN104161769B CN 104161769 B CN104161769 B CN 104161769B CN 201410404023 A CN201410404023 A CN 201410404023A CN 104161769 B CN104161769 B CN 104161769B
- Authority
- CN
- China
- Prior art keywords
- adenosine cyclophosphate
- compositions containing
- diphenhydramine
- containing adenosine
- vinpocetine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention discloses a kind of compositions containing adenosine cyclophosphate and application thereof, the formula number meter of said composition, is made up of 10-12 part adenosine cyclophosphate, 6-9 part diphenhydramine, 5-8 part vinpocetine and 2-3 part nicotinic acid.Compositions containing adenosine cyclophosphate of the present invention, by adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid compatibility, serves the effect for the treatment of myocardial infarction well.
Description
Technical field
The present invention relates to new drug development technical field, particularly relate to the exploitation for the treatment of of myocardial infarction medicine, be specifically related to a kind of compositions containing adenosine cyclophosphate and application thereof.
Background technology
Myocardial infarction is that coronary artery is acute, impatient necrosis caused by persistence Hypoxia and ischemia.Because of the change of modern's living habit, the appearance of the problems such as the quickening of rhythm of life, the sickness rate of China's myocardial infarction is in recent years obvious ascendant trend, newly send to few 500,000 every year, now suffer from least 200 ten thousand, therefore, be devoted to research and develop new effective treatment of myocardial infarction medicine, tool has very important significance and wide market prospect.
Adenosine cyclophosphate, chemical name is 6-amino-9-β-D-RIBOSE base-9H-purine-4`, and 5`-cycli phosphate hydrogen ester, molecular formula is C
10h
12n
5o
6p is white or off-white powder; Adenosine cyclophosphate is as participating in the second message,second messenger's material regulating cell function, and widely, the adenosine cyclophosphate that injection is heavy dose of, myocardial contraction can be made to strengthen, and cause elevation of the blood pressure, cardiac output increases in its effect.And can diastole smooth muscle, coronary artery dilator blood vessel, improve liver function, suppress the division of skin outer layer epithelial cell and transform paracytic function, promote the oxidasic activity of respiratory chain and improve myocardial ischemia etc.
Diphenhydramine, molecular formula is C
17h
21nOHCl is white crystalline powder; Diphenhydramine is antihistaminic, has the effect of antihistaminic H1 receptor, has stronger inhibitory action to nervus centralis.
Vinpocetine, molecular formula is C
22h
26n
2o
2, be white loose block or powder, be usually used in improving the various symptoms that cerebral infarction sequela, apoplexy sequela, cerebral arteriosclerosis etc. are brought out.
Nicotinic acid, also referred to as vitamin B
3, molecular formula is C
6h
5nO
2, colorless needle crystals, has stronger expansion peripheral vessels effect, is clinically used for the treatment of headache, migraine, tinnitus, auditory vertigo etc.
At present, there is not yet correlational study diphenhydramine, vinpocetine being used for treatment of myocardial infarction, also do not have correlational study report diphenhydramine, vinpocetine and nicotinic acid collocation adenosine cyclophosphate being used for the treatment of myocardial infarction.
Summary of the invention
The object of this invention is to provide a kind of be used for the treatment of myocardial infarction, containing the compositions of adenosine cyclophosphate.
Another object of the present invention is to provide the application of above-mentioned composition in preparation treatment myocardial infarction medicine.
Above-mentioned purpose of the present invention is achieved by following scheme:
Containing a compositions for adenosine cyclophosphate, the formula of said composition is made up of each component of following parts by weight:
The preferred version of combinations thereof composition formula is as follows:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and after crossing 100 mesh sieves, according to formula consumption, mixing, drier 30 minutes of the baking oven putting into 55-60 DEG C, then prepare the compositions containing adenosine cyclophosphate of the present invention.
The above-mentioned compositions containing adenosine cyclophosphate can make various dosage form with pharmaceutically acceptable carrier or excipient, as tablet, granule, capsule or injection etc.
Compositions containing adenosine cyclophosphate of the present invention, through experimentation, has well treatment myocardial infarction effect, therefore, can be used for the medicine preparing treatment myocardial infarction.
Compared with prior art, the present invention has following beneficial effect:
1. the compositions containing adenosine cyclophosphate of the present invention, introduces diphenhydramine, vinpocetine in the research for the treatment of myocardial infarction medicine first, by by adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid compatibility, serves the effect for the treatment of myocardial infarction well;
2. the compositions containing adenosine cyclophosphate of the present invention, in its formula, each composition is all that basic research and clinical practice confirm do not have obvious toxic-side effects, and does not have the taboo of compatibility between each composition, without mutual ill effect, therefore has safety.
Detailed description of the invention
Below in conjunction with specific embodiment the present invention done and describe further, but specific embodiment does not do any restriction to the present invention.
Embodiment 1
Compositions containing adenosine cyclophosphate of the present invention, the formula of said composition is made up of each component of following parts by weight:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and after crossing 100 mesh sieves, according to formula consumption, mixing, drier 30 minutes of the baking oven putting into 55-60 DEG C, then prepare the compositions containing adenosine cyclophosphate of the present embodiment.
Embodiment 2
Compositions containing adenosine cyclophosphate of the present invention, the formula of said composition is made up of each component of following parts by weight:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and after crossing 100 mesh sieves, according to formula consumption, mixing, drier 30 minutes of the baking oven putting into 55-60 DEG C, then prepare the compositions containing adenosine cyclophosphate of the present embodiment.
Embodiment 3
Compositions containing adenosine cyclophosphate of the present invention, the formula of said composition is made up of each component of following parts by weight:
The preparation method of the above-mentioned compositions containing adenosine cyclophosphate is as follows:
Adenosine cyclophosphate, diphenhydramine, vinpocetine and nicotinic acid are ground respectively and after crossing 100 mesh sieves, according to formula consumption, mixing, drier 30 minutes of the baking oven putting into 55-60 DEG C, then prepare the compositions containing adenosine cyclophosphate of the present embodiment.
Comparative example 1
The compositions of this comparative example, its formula is made up of each component of following parts by weight:
Diphenhydramine 8 parts;
Vinpocetine 6 parts;
2 parts, nicotinic acid.
The preparation method of above-mentioned composition is as follows:
Diphenhydramine, vinpocetine and nicotinic acid are ground respectively and after crossing 100 mesh sieves, according to formula consumption, mixing, drier 30 minutes of the baking oven putting into 55-60 DEG C, then prepare the compositions of this comparative example.
Embodiment 4 myocardial infarction model is tested
Take mice as experimental subject, often organize 10 mices, establish 6 groups altogether, shown in specific as follows:
(1) blank group: experimental drug is water for injection.
(2) experimental group 1: experimental drug is a kind of compositions containing adenosine cyclophosphate prepared by embodiment 1;
(3) experimental group 2: experimental drug is a kind of compositions containing adenosine cyclophosphate prepared by embodiment 2;
(4) experimental group 3: experimental drug is a kind of compositions containing adenosine cyclophosphate prepared by embodiment 3;
(5) matched group 1: experimental drug is compositions prepared by comparative example 1;
(6) matched group 2: experimental drug is adenosine cyclophosphate.
Experimental model is myocardial infarction model, after causing each group of experiment mice myocardial necrosis with isoproterenol, and intravenously administrable, twice daily, the dosage of each experimental drug is 5mg/kg, and administration is after 20 days, observe mice survival rate (%), result is as follows:
(1) blank group: survival rate 0;
(2) experimental group 1: survival rate 90%;
(3) experimental group 2: survival rate 90%;
(4) experimental group 3: survival rate 100%;
(5) matched group 1: survival rate 20%;
(6) matched group 2: survival rate 70%.
As can be seen from above-mentioned experimental result, as compared to using merely adenosine cyclophosphate or use diphenhydramine, vinpocetine to combine with nicotinic acid, the compositions containing adenosine cyclophosphate of the present invention has the effect of well treatment myocardial infarction.
Claims (1)
1., containing a compositions for adenosine cyclophosphate, it is characterized in that the formula of said composition is made up of each component of following parts by weight:
Adenosine cyclophosphate 11 parts;
Diphenhydramine 8 parts;
Vinpocetine 6 parts;
2 parts, nicotinic acid.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410404023.9A CN104161769B (en) | 2014-08-16 | 2014-08-16 | A kind of compositions containing adenosine cyclophosphate and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410404023.9A CN104161769B (en) | 2014-08-16 | 2014-08-16 | A kind of compositions containing adenosine cyclophosphate and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN104161769A CN104161769A (en) | 2014-11-26 |
| CN104161769B true CN104161769B (en) | 2016-01-20 |
Family
ID=51905895
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410404023.9A Active CN104161769B (en) | 2014-08-16 | 2014-08-16 | A kind of compositions containing adenosine cyclophosphate and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN104161769B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562346A (en) * | 2004-04-05 | 2005-01-12 | 杨喜鸿 | Compound preparation of cyclicamp or its ramification and counteractant for free radical |
| CN101791310A (en) * | 2010-02-24 | 2010-08-04 | 王保明 | Vinpocetine medicine composition and preparation method thereof |
| CN102802618A (en) * | 2009-06-25 | 2012-11-28 | 泰特拉有限公司 | Therapeutic Combinations Of Nicotinic Acid And Meldonium |
-
2014
- 2014-08-16 CN CN201410404023.9A patent/CN104161769B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1562346A (en) * | 2004-04-05 | 2005-01-12 | 杨喜鸿 | Compound preparation of cyclicamp or its ramification and counteractant for free radical |
| CN102802618A (en) * | 2009-06-25 | 2012-11-28 | 泰特拉有限公司 | Therapeutic Combinations Of Nicotinic Acid And Meldonium |
| CN101791310A (en) * | 2010-02-24 | 2010-08-04 | 王保明 | Vinpocetine medicine composition and preparation method thereof |
Non-Patent Citations (1)
| Title |
|---|
| HPLG法测定冠心膏中盐酸苯海拉明的含量;李兴、段立广;《中国实用医药》;20120430;第7卷(第12期);260－261 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN104161769A (en) | 2014-11-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20170266213A1 (en) | Use of beta-nicotinamide mononucleotide in preparation of anti-aging drugs or health-care products | |
| CN102958523B (en) | Antitumor agent using compounds having kinase inhibitory effect in combination | |
| CN106822905B (en) | The drug and purposes of inhibitor containing Survivin and IRE1 inhibitor | |
| US20170080011A1 (en) | Use of nadh and nmn in preparation of drugs or health-care products for treating parkinson's disease | |
| CN108721281A (en) | New antiviral drugs and its application | |
| CN103263416A (en) | Application of pyridylamine compound in preparation of drugs used for treating lung cancer and suitable for oral administration | |
| CN104161769B (en) | A kind of compositions containing adenosine cyclophosphate and application thereof | |
| CN101541717B (en) | A trans-cinnamic acid derivative, its preparation method and the use | |
| MX2019007360A (en) | Azabicyclo-substituted triazole derivative, preparation method thereof, and application of same in medicine. | |
| CN101757016A (en) | Medicine composition for treating flu and preparation method thereof | |
| CN102885809B (en) | Application of Aphanamixoid A in preparing medicament for treating pancreatic cancer | |
| CN105902531A (en) | Medicine composition for inhibiting liver fibroblast proliferation, preparation method and application thereof | |
| CN105726597A (en) | Pulvis for preventing and treating chicken coccidiosis and preparation method thereof | |
| CN105726558A (en) | Composition containing meglumine adenosine cyclophosphate and application thereof | |
| CN105456272A (en) | Application of Biscarpamontamine A in preparing medicine for increasing red blood cells | |
| CN103405438B (en) | Trapidil or the application of its pharmaceutically acceptable salt in preparation control pulmonary hypertension medicine | |
| CN104644666A (en) | Medicine for treating coronary heart disease | |
| CN104127467A (en) | Borage-based traditional Chinese medicine granule, preparation method, application method and use thereof | |
| CN103463032B (en) | Application of Lycojaponicumin A in preparation of pancreatic cancer treatment drug | |
| CN103860561B (en) | A kind of pharmaceutical composition and application thereof preventing and treating breast carcinoma | |
| CN103961386A (en) | Application of traditional Chinese medicine composition in preparing drugs for treating pancreatic cancer | |
| CN102872111B (en) | Application of Houttuynoid C in medicament for treating pancreatic cancer | |
| CN102872122B (en) | Application of Houttuynoid B in medicament for treating pancreatic cancer | |
| CN103127107A (en) | Application of levamlodipine or and salts thereof to treatment of liver cancer | |
| CN103356637A (en) | Application of chaetocin in preparation of medicine used for preventing and treating heart diseases |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221111 Address after: No.6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone, Guangdong 510000 Patentee after: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. Patentee after: GUANGDONG ZERUI PHARMACEUTICAL Co.,Ltd. Patentee after: Guangzhou Lianrui Pharmaceutical Co.,Ltd. Patentee after: Guangzhou Runlin Pharmaceutical Technology Co.,Ltd. Patentee after: Euphorbia Biological Medicine Co.,Ltd. Address before: Building 1, No. 6, Dongbo Road, Guangzhou Economic and Technological Development Zone, Guangzhou, Guangdong 510765 Patentee before: GUANGZHOU YIPINHONG PHARMACEUTICAL Co.,Ltd. |
|
| TR01 | Transfer of patent right |